These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 25999431)

  • 21. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
    Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First In-Human Medical Imaging with a PASylated
    Richter A; Knorr K; Schlapschy M; Robu S; Morath V; Mendler C; Yen HY; Steiger K; Kiechle M; Weber W; Skerra A; Schwaiger M
    Nucl Med Mol Imaging; 2020 Apr; 54(2):114-119. PubMed ID: 32377263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
    Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
    Houghton JL; Zeglis BM; Abdel-Atti D; Sawada R; Scholz WW; Lewis JS
    J Nucl Med; 2016 Mar; 57(3):453-9. PubMed ID: 26471693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.
    Shi S; Orbay H; Yang Y; Graves SA; Nayak TR; Hong H; Hernandez R; Luo H; Goel S; Theuer CP; Nickles RJ; Cai W
    J Nucl Med; 2015 Jun; 56(6):927-32. PubMed ID: 25883125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
    Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
    Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
    Jagoda EM; Lang L; Bhadrasetty V; Histed S; Williams M; Kramer-Marek G; Mena E; Rosenblum L; Marik J; Tinianow JN; Merchant M; Szajek L; Paik C; Cecchi F; Raffensperger K; Jose-Dizon JM; Bottaro DP; Choyke P
    J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
    Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.
    Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B
    Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
    Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
    J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.